Sarepta Therapeutics (SRPT)
(Delayed Data from NSDQ)
$127.08 USD
+2.83 (2.28%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $127.12 +0.04 (0.03%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$127.08 USD
+2.83 (2.28%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $127.12 +0.04 (0.03%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Zacks News
Gilead Sciences (GILD) Stock Gains 20% YTD: What Lies Ahead?
by Zacks Equity Research
Gilead's (GILD) performance in the year has been pretty good on contribution from Veklury. The company is now focusing on its oncology business as the virology business faces challenges.
Selecta (SELB) Down on FDA's Clinical Hold on Phase I/II Study
by Zacks Equity Research
The FDA issues a clinical hold on Selecta's (SELB) phase I/II study evaluating SEL-302 for the treatment of patients with methylmalonic acidemia. Shares down in after-hours trading.
Bristol Myers (BMY) Zeposia Gets EC Nod for Ulcerative Colitis
by Zacks Equity Research
Bristol Myers (BMY) wins EC approval for Zeposia for a second indication ??? ulcerative colitis.
REGENXBIO (RGNX) DMD Gene Therapy Gets Orphan Drug Status
by Zacks Equity Research
REGENXBIO (RGNX) is developing a gene therapy candidate, RGX-202, for treating DMD, which is currently in the pre-clinical stage. An IND application is expected by the end of 2021.
bluebird (BLUE) Filing for Thalassemia Therapy Gets Priority Review
by Zacks Equity Research
bluebird (BLUE) application seeking approval for beti-cel for thalassemia gets priority review in the United States.
BioMarin's (BMRN) Dwarfism Drug Gets FDA's Nod, Stock Up
by Zacks Equity Research
Biomarin Pharmaceuticals's (BMRN) Voxzogo is the first medicine in the United States to be approved to treat achondroplasia, the most common form of dwarfism.
Roche (RHHBY) Gets Approval for Gavreto for NSCLC in EU
by Zacks Equity Research
Roche (RHHBY) wins EC approval for Gavreto for the treatment of adults with RET fusion-positive advanced NSCLC.
Bristol Myers' (BMY) Cardiovascular Drug Review Extended by FDA
by Zacks Equity Research
Bristol Myers (BMY) announces extension of FDA review of its cardiovascular drug mavacamten. The new target action date is Apr 28, 2022.
Biogen's (BIIB) Aducanumab Gets CHMP's Negative Trend Vote
by Zacks Equity Research
Biogen's (BIIB) regulatory application seeking approval for its Alzheimer's drug, Aduhelm, in Europe hits setback as it receives negative trend vote from the CHMP.
Biogen's (BIIB) Oral MS Drug Vumerity Gets Approval in Europe
by Zacks Equity Research
Biogen's (BIIB) Vumerity gets marketing authorization in Europe for the treatment of adults with relapsing-remitting multiple sclerosis.
PhaseBio (PHAS) Dips on Mixed Data From Antiplatelet Drug Study
by Zacks Equity Research
PhaseBio's (PHAS) phase III study evaluating bentracimab for the reversal of antiplatelet effects of ticagrelor meets primary endpoint. The stock falls on high rates of the drug's side effects.
ChemoCentryx (CCXI) Gets Positive CHMP Opinion for Tavneos
by Zacks Equity Research
ChemoCentryx (CCXI) receives a positive recommendation from the CHMP for its lead drug Tavneos to treat two forms of ANCA-associated vasculitis.
Gilead (GILD), Everest Medicine Report Phase II Cancer Study Data (Revised)
by Zacks Equity Research
Gilead (GLD) and partner Everest Medicine report that the mid-stage study of sacituzumab govitecan for triple-negative breast cancer achieved its main goal.
Biogen (BIIB) Up on New Data From Phase III Studies on Aduhelm
by Zacks Equity Research
Biogen's (BIIB) Aduhelm significantly lowers plasma p-tau-181, a pathological hallmark of Alzheimer's disease, in phase III studies.
Gilead (GILD), Everest Medicine Report Phase II Cancer Study Data
by Zacks Equity Research
Gilead (GLD) and partner Everest Medicine report that the mid-stage study of sacituzumab govitecan for triple-negative breast cancer achieved its main goal.
Sarepta (SRPT) Q3 Earnings Beat, 2021 Sales View Raised
by Zacks Equity Research
Strong demand for Sarepta's (SRPT) DMD drugs boosts its top line in the third quarter. The company also raises revenues guidance for the year. Stock up in after-market trading.
Sarepta Therapeutics (SRPT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 67.74% and 11.33%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights: CRISPR Therapeutics, Editas Medicine, Sarepta Therapeutics and Beam Therapeutics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: CRISPR Therapeutics, Editas Medicine, Sarepta Therapeutics and Beam Therapeutics
4 Biotechs to Watch Amid Rising Prominence of Gene Therapies
by Indrajit Bandyopadhyay
Here we discuss four biotech companies, CRSP, EDIT, SRPT and BEAM, that have the potential to gain from their promising gene therapy pipeline candidates.
Sarepta (SRPT) Begins Pivotal Study on DMD Gene Therapy
by Zacks Equity Research
Sarepta (SRPT) is developing its lead gene therapy candidate, SRP-9001, as a potential one-time treatment for DMD.
5 Gene Therapy Stocks Back in Focus on AbbVie/Regenxbio Deal
by Kinjel Shah
The promising gene therapy approach is being evaluated for varied diseases, such as hemophilia, Duchenne muscular dystrophy (DMD), Parkinson's disease, eye disease, and cancer among others
Sarepta Therapeutics (SRPT) Up 1.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Sarepta (SRPT) Q2 Earnings Beat, 2021 Sales View Raised
by Zacks Equity Research
Strong demand for Sarepta's (SRPT) DMD drugs boosts its top line in Q2. The company also raises revenues guidance for the year. It plans to start a pivotal study on SRP-9001 next month. Stock up.
Sarepta Therapeutics (SRPT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 0.97% and 11.29%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
BioNTech (BNTX) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On BioNTech's (BNTX) second-quarter earnings call, investors' focus will be on sales number of BNT162b2, its COVID-19 vaccine, developed in partnership with Pfizer.